pure bioscience - PURE

PURE

Close Chg Chg %
0.05 0.00 0.00%

Closed Market

0.05

0.00 (0.00%)

Volume: 1.28K

Last Updated:

Dec 23, 2025, 2:39 PM EDT

Company Overview: pure bioscience - PURE

PURE Key Data

Open

$0.05

Day Range

0.05 - 0.05

52 Week Range

0.04 - 0.21

Market Cap

$5.59M

Shares Outstanding

111.89M

Public Float

65.73M

Beta

0.39

Rev. Per Employee

N/A

P/E Ratio

N/A

EPS

-$0.02

Yield

0.00%

Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

65.99K

 

PURE Performance

1 Week
 
-0.22%
 
1 Month
 
-3.34%
 
3 Months
 
-44.22%
 
1 Year
 
-25.44%
 
5 Years
 
-93.74%
 

PURE Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 1
Full Ratings ➔

About pure bioscience - PURE

PURE Bioscience, Inc. engages in the discovery, development, and commercialization of proprietary antimicrobial products for pathogen and hygienic control. It offers silver dihydrogen citrate-based disinfecting and sanitizing products. The company was founded by Michael L. Krall on August 24, 1992 and is headquartered in El Cajon, CA.

PURE At a Glance

PURE Bioscience, Inc.
771 Jamacha Road
El Cajon, California 92019
Phone 1-619-596-8600 Revenue 2.20M
Industry Chemicals: Major Diversified Net Income -2,399,000.00
Sector Process Industries 2025 Sales Growth 12.175%
Fiscal Year-end 07 / 2026 Employees 12
View SEC Filings

PURE Valuation

P/E Current N/A
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio 4.562
Price to Book Ratio N/A
Price to Cash Flow Ratio N/A
Enterprise Value to EBITDA -6.552
Enterprise Value to Sales 6.754
Total Debt to Enterprise Value 0.352

PURE Efficiency

Revenue/Employee 183,500.00
Income Per Employee -199,916.667
Receivables Turnover 4.646
Total Asset Turnover 2.348

PURE Liquidity

Current Ratio 1.116
Quick Ratio 0.966
Cash Ratio 0.436

PURE Profitability

Gross Margin 59.173
Operating Margin -103.179
Pretax Margin -108.946
Net Margin -108.946
Return on Assets -255.757
Return on Equity N/A
Return on Total Capital -1,999.167
Return on Invested Capital -2,340.488

PURE Capital Structure

Total Debt to Total Equity N/A
Total Debt to Total Capital 4,363.333
Total Debt to Total Assets 494.896
Long-Term Debt to Equity N/A
Long-Term Debt to Total Capital 4,363.333
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Pure Bioscience - PURE

Collapse All in section
All values USD millions. 2022 2023 2024 2025 5-year trend
Sales/Revenue
1.85M 1.88M 1.96M 2.20M
Sales Growth
-52.81% +1.30% +4.58% +12.18%
Cost of Goods Sold (COGS) incl D&A
853.00K 906.00K 811.00K 899.00K
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
213.00K 117.00K 148.00K 2.00K
Depreciation
146.00K 117.00K 148.00K 2.00K
Amortization of Intangibles
- - - 67.00K
-
COGS Growth
-53.94% +6.21% -10.49% +10.85%
Gross Income
1.00M 971.00K 1.15M 1.30M
Gross Income Growth
-51.81% -2.90% +18.64% +13.11%
Gross Profit Margin
+53.97% +51.73% +58.69% +59.17%
2022 2023 2024 2025 5-year trend
SG&A Expense
4.42M 4.60M 4.28M 3.58M
Research & Development
319.00K 297.00K 302.00K 316.00K
Other SG&A
4.11M 4.30M 3.98M 3.26M
SGA Growth
+0.89% +3.93% -6.87% -16.53%
Other Operating Expense
- - - -
-
Unusual Expense
- 60.00K 315.00K 60.00K
EBIT after Unusual Expense
(3.48M) (3.94M) (3.19M) (2.27M)
Non Operating Income/Expense
- (4.00K) (4.00K) 172.00K
Non-Operating Interest Income
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
6.00K 14.00K 155.00K 299.00K
Interest Expense Growth
+50.00% +133.33% +1,007.14% +92.90%
Gross Interest Expense
6.00K 14.00K 155.00K 299.00K
Interest Capitalized
- - - -
-
Pretax Income
(3.49M) (3.96M) (3.35M) (2.40M)
Pretax Income Growth
-50.54% -13.46% +15.43% +28.39%
Pretax Margin
-188.40% -211.03% -170.66% -108.95%
Income Tax
- - - -
-
Income Tax - Current - Domestic
- - - -
-
Income Tax - Current - Foreign
- - - -
-
Income Tax - Deferred - Domestic
- - - -
-
Income Tax - Deferred - Foreign
- - - -
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
(3.49M) (3.96M) (3.35M) (2.40M)
Minority Interest Expense
- - - -
-
Net Income
(3.49M) (3.96M) (3.35M) (2.40M)
Net Income Growth
-50.54% -13.46% +15.43% +28.39%
Net Margin Growth
-188.40% -211.03% -170.66% -108.95%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
(3.49M) (3.96M) (3.35M) (2.40M)
Preferred Dividends
- - - -
-
Net Income Available to Common
(3.49M) (3.96M) (3.35M) (2.40M)
EPS (Basic)
-0.0393 -0.0356 -0.03 -0.0214
EPS (Basic) Growth
-47.74% +9.41% +15.73% +28.67%
Basic Shares Outstanding
88.84M 111.40M 111.86M 111.86M
EPS (Diluted)
-0.0393 -0.0356 -0.03 -0.0214
EPS (Diluted) Growth
-47.74% +9.41% +15.73% +28.67%
Diluted Shares Outstanding
88.84M 111.40M 111.86M 111.86M
EBITDA
(3.21M) (3.51M) (2.98M) (2.27M)
EBITDA Growth
-50.16% -9.31% +15.04% +23.90%
EBITDA Margin
-173.34% -187.05% -151.96% -103.09%

Pure Bioscience in the News